Skip to content
Yakup Ergün· @dr_yakupergun · X·· 2026-04-18Score60

daraxonrasib

Reading

KRAS / RAS targeting: from platform to Phase 3

The floor also showed dual ON/OFF (VS-7375) and RM-055, built for amplification and daraxonrasib-resistant models.

The floor rewrote the question from “how long can G12C monotherapy last” to “who first makes first-line pancreatic cancer a standard.” daraxonrasib’s Phase 3 is still the only RAS-inhibitor overall-survival win.

Body

#AACR26
Daraxonrasib monotherapy, a RAS(ON) multi-selective inhibitor, is also making its mark

In 1L mPDAC: ORR 47–51%
DCR 92–97%
6-month PFS 71%
6-month OS 83%

For a chemotherapy-free approach in pancreatic cancer, these results are highly encouraging

https://
aacrjournals.org/cancerres/arti
cle/86/8_Supplement/LB337/782959/Abstract-LB337-Daraxonrasib-monotherapy-as-first?searchresult=1
…

Heat 36 · 28 likes · 0 replies · 8 reposts

Conference abstracts
LB407NCT05379985NCT06445062matched by 药名 daraxonrasib
Daraxonrasib plus chemotherapy (CT) as first-line (1L) treatment for patients (Pts) with metastatic pancreatic adenocarcinoma (mPDAC)

Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, Joel Randolph Hecht, Shubham Pant, Shiraj Sen, E. Gabriela Chiorean, W. Clay Gustafson, Hina Patel, Vidya Seshadri, Yan Zheng, Davendra Sohal

Read the abstract →

Source: Yakup Ergün · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org